Bionovo, Inc. operates as a late stage clinical drug discovery and development company focusing on womenâ€™s health and cancer primarily in the United States. The companyâ€™s drug development process utilizes botanical sources used in traditional Chinese medicine to produce biologically active compounds. Its lead drug candidate is Menerba, a receptor sub-type selective estrogen receptor modulator, which is in Phase III clinical trial for the treatment of vasomotor symptoms of menopause. The company is also developing Bezielle, an oral anti-cancer agent that in Phase II clinical trail for the treatment of advanced breast cancer; and Seala for the treatment of post-menopausal vulvar and vaginal atrophy. Bionovo, Inc. was founded in 2002 and is headquartered in Emeryville, California. On October 26, 2012, Bionovo, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Northern District of California.